Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

Clicks: 276
ID: 271175
2008
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
PCWG2 recommends increasing emphasis on time-to-event end points (ie, failure to progress) as decision aids in proceeding from phase II to phase III trials. Recommendations will evolve as data are generated on the utility of intermediate end points to predict clinical benefit.
Reference Key
hi2008journaldesign Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Scher HI;Halabi S;Tannock I;Morris M;Sternberg CN;Carducci MA;Eisenberger MA;Higano C;Bubley GJ;Dreicer R;Petrylak D;Kantoff P;Basch E;Kelly WK;Figg WD;Small EJ;Beer TM;Wilding G;Martin A;Hussain M; ;;
Journal journal of clinical oncology : official journal of the american society of clinical oncology
Year 2008
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18309951
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't u.s. gov't non-p.h.s. male N.I.H. Extramural outcome assessment guideline disease progression patient selection testosterone / blood* guidelines as topic adenocarcinoma / pathology* adenocarcinoma / therapy clinical trials as topic / standards* research design / standards* health care / standards prostatic neoplasms / pathology* investigators=[] affs=[]) prostatic neoplasms / therapy pmid:18309951 pmc4010133 doi:10.1200/jco.2007.12.4487 howard i scher susan halabi collabauthor(name='prostate cancer clinical trials working group' adenocarcinoma / blood endpoint determination* prostate-specific antigen / blood prostatic neoplasms / blood

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.